Infliximab in Refractory Psoriatic Arthritis with Severe Psoriasis: a 2-year Experience

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2006 Oct 28

PMID 17068063

Citations 3

Authors

Paraskevi V Voulgari

Aliki I Venetsanopoulou

Efstratios K Epagelis

Yannis Alamanos

Ioanna Takalou

Alexandros A Drosos

Affiliations

Soon will be listed here.

Citing Articles

Advances in nanomedicine for the treatment of ankylosing spondylitis.

Xi Y, Jiang T, Chaurasiya B, Zhou Y, Yu J, Wen J Int J Nanomedicine. 2019; 14:8521-8542.

PMID: 31806960 PMC: 6831987. DOI: 10.2147/IJN.S216199.

A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review.

Saougou I, Papagoras C, Markatseli T, Voulgari P, Drosos A Clin Rheumatol. 2010; 29(12):1455-9.

PMID: 20490588 DOI: 10.1007/s10067-010-1485-4.

Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment.

Shaikh S J Can Chiropr Assoc. 2007; 51(4):249-60.

PMID: 18060011 PMC: 2077878.

References

Temekonidis T, Georgiadis A, Alamanos Y, Bougias D, Voulgari P, Drosos A . Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis. 2002; 61(9):822-5. PMC: 1754214. DOI: 10.1136/ard.61.9.822. View

Antoni C, Dechant C, Wendler J, Ogilvie A, Lueftl M, Kalden J . Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002; 47(5):506-12. DOI: 10.1002/art.10671. View

Feletar M, Brockbank J, Schentag C, Lapp V, Gladman D . Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004; 63(2):156-61. PMC: 1754892. DOI: 10.1136/ard.2003.006775. View

Gladman D, Helliwell P, Mease P, Nash P, Ritchlin C, Taylor W . Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004; 50(1):24-35. DOI: 10.1002/art.11417. View

Nikas S, Voulgari P, Takalou I, Katsimbri P, Drosos A . Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. Ann Rheum Dis. 2005; 64(11):1665-7. PMC: 1755277. DOI: 10.1136/ard.2005.036178. View

Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-35. DOI: 10.1002/art.1780380602. View

Ashcroft D, Wan Po A, Williams H, Griffiths C . Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141(2):185-91. DOI: 10.1046/j.1365-2133.1999.02963.x. View

Antoni C, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester G, Schneider U . Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005; 52(4):1227-36. DOI: 10.1002/art.20967. View

Antoni C, Krueger G, de Vlam K, Birbara C, Beutler A, Guzzo C . Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64(8):1150-7. PMC: 1755609. DOI: 10.1136/ard.2004.032268. View

10.

Prevoo M, van t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44-8. DOI: 10.1002/art.1780380107. View